Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 14,759 matching trials from the live ClinicalTrials.gov search.
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas
Interventions
Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 3 Interventional Results available

A Trial to Reduce Pneumonia in Nursing Home Residents

NCT00975780
Conditions
Pneumonia, Lower Respiratory Tract Infection
Interventions
Enhanced Oral Care, Usual oral care
Other
Lead sponsor
Yale University
Other
Eligibility
65 Years and older
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
COVID-19
Interventions
Aluminum Hydroxide Suspension, Boost-2867, CpG 7909, Sodium Chloride, 0.9%
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Fullerton, California • Peoria, Illinois • The Bronx, New York + 1 more
Conditions
Covid19, Pneumonia, Viral
Interventions
alpha1-proteinase inhibitor, Antiviral Agents
Drug
Lead sponsor
Blessing Corporate Services, Inc
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Hannibal, Missouri
Conditions
Cystic Fibrosis
Interventions
VX-581, Placebo, D-IVA, TEZ, ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
Interventions
FlowTriever System, Anticoagulation Agents
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 47 more
Conditions
Asthma
Interventions
Reslizumab, Saline
Biological · Other
Lead sponsor
Ception Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
24
States / cities
Orange, California • Centennial, Colorado • Colorado Springs, Colorado + 20 more
Conditions
Asthma
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
66
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 54 more
Conditions
Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injury, Acute, Spinal Cord Injury, Spinal Cord Injury, Chronic
Interventions
OPC1
Biological
Lead sponsor
Lineage Cell Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
2
States / cities
Downey, California • La Jolla, California
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS)
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
90
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more
Conditions
Non Small Cell Lung Cancer
Interventions
Ipilimumab, Nivolumab, SBRT
Drug · Radiation
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Asthma
Interventions
BreatheSmart System, Standard of Care
Device · Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Hartford, Connecticut
Conditions
Non-small Cell Lung Cancer
Interventions
Pevonedistat, Docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Non-small Cell Lung Cancer
Interventions
Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
58
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 53 more
Conditions
Lung Neoplasms
Interventions
Pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
37
States / cities
Mobile, Alabama • Glendale, Arizona • Anaheim, California + 34 more
Conditions
Histiocytosis, Langerhans-Cell
Interventions
Etanercept
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Day to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Conditions
Coronary Artery Disease, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
COVID-19
Interventions
Povidone-Iodine 2%, Povidone-Iodine 0.5%, Isotonic saline 0.9%
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Stanford, California
Conditions
Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, Malignant Glioma
Interventions
2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks, 2B3-101 50 mg/m2 every 3 weeks
Drug
Lead sponsor
BBB-Therapeutics B.V.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Solid Tumor, Adult, Solid Tumor Cancer
Interventions
DF6215, pembrolizumab, KEYTRUDA®
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 5 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Different Flow Settings on Lung Impedance

NCT06228703
Conditions
Healthy
Interventions
High-flow nasal cannula device with flow setting at 40 L/min or higher
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Forest Park, Illinois
Conditions
Pneumonia
Interventions
clarithromycin extended release (ER), azithromycin SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 24 more
Terminated Not applicable Interventional

ASTHMAXcel Emergency Department Study

NCT05013073
Conditions
Asthma, Asthma Attack
Interventions
ASTHMAXcel ED Application
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
The Bronx, New York